[Serum lipid-lowering drugs following myocardial infarction].
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D003918:Dextrothyroxine / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D005260:Female; D005860:Germany, West; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood; D014481:United States
D004966:Estrogens, Conjugated (USP); D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D014280:Triglycerides; D003918:Dextrothyroxine; D002784:Cholesterol; D002994:Clofibrate
Serumlipidsenkende Pharmaka nach Myokardinfarkt